Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000646

Drug Information
NameSunitinib malate
SynonymsSU010398; N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; (2S)-2-hydroxybutanedioic acid; PNU-290940AD; SU011248; SU-010398; PHA-290940AD; AKOS005145765; FT-0083555; Sunitinib malate [USAN]; Sutent, SU-11248; D06402; SU-011248 L-malate salt; Sunitinib malate; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate; ST51053712; Sutent (TN); AC1O5CMQ; CHEMBL1567; 341031-54-7; LS-186078; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); CHEBI:550864; MolPort-003-986-763; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1); SU011248 L-malate salt; TL8002546; Sunitinib malate (JAN/USAN); UNII-LVX8N1UT73; CID6456015; Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1); SU-11248 L-malate salt; SU 011248; S1042_Selleck
Trade NameSutent
IndicationMetastatic Renal Cell Carcinoma; Gastrointestinal Stromal Tumors
[ICD9: 140-199, 150-159, 189, 210-229   ICD10: C00-C75, C15-C26, C64, C7A, C7B, D10-D36, D3A]
Phase IV    [1]
Soft Tissue Sarcoma
[ICD9: 171   ICD10: C49]
Phase II    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=
Isomeric SMILESCCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=
CAS NumberCAS 557795-19-4
PubChem Compound IDCID 6456015.
PubChem Substance IDSID 10560397.
SuperDrug ATC IDL01XE04
TargetFL cytokine receptorInhibitor[2][3][4]
FL cytokine receptorMultitarget[2][3][4]
Mast/stem cell growth factor receptorInhibitor[2][3][4]
Mast/stem cell growth factor receptorMultitarget[2][3][4]
Platelet-derived growth factor receptorInhibitor[2][3][4]
Platelet-derived growth factor receptorMultitarget[2][3][4]
Vascular endothelial growth factor receptor 2Inhibitor[2][3][4]
Vascular endothelial growth factor receptor 2Multitarget[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Pfizer. Product Development Pipeline. March 31 2009. To Reference
Ref 3Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. Epub 2008 Oct 29. To Reference
Ref 4A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543